Zealand Pharma – advancing medicines for obesity and metabolic health

Share price information

ZEAL (COP)
280.40DKK

Last updated on 18 September 2026 10:01 (GMT +01:00)

Zealand Pharma is listed on Nasdaq Copenhagen under the ticker symbol ZEAL.
More Stock information
Annual Report 2025

Read Zealand Pharma's annual report for 2025.
Download report
Corporate presentation

See Zealand Pharma's latest Corporate Presentation for an overview of our R&D pipeline and additional company information.
Download Presentation

COMPANY ANNOUNCEMENT 14 Sep 2026

Zealand Pharma - Transactions related to share buy-back program (week 37, 2026)
READ MORE
COMPANY ANNOUNCEMENT 10 Sep 2026

Zealand Pharma increases its share capital as a result of the exercise of employee warrants
READ MORE
PRESS RELEASE 09 Sep 2026

Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference
READ MORE
COMPANY ANNOUNCEMENT 07 Sep 2026

Zealand Pharma - Transactions related to share buy-back program (week 36, 2026)
READ MORE

Obesity

Petrelintide

A long-acting amylin analog as a weight-loss medication representing an alternative to GLP-1 receptor agonists.

Obesity

Survodutide

A long-acting glucagon/GLP-1 receptor dual agonist targeting obesity and MASH licensed to Boehringer Ingelheim.

Chronic inflammation

ZP9830

A potent and selective blocker of the Kv1.3 ion channel with the potential to treat a broad range of T-cell-driven autoimmune diseases.

Obesity

ZP6590

A GIP receptor agonist targeting obesity as a potential complement to GLP-1 for increased effect and/or tolerability.

Congenital Hyperinsulinism

Dasiglucagon: Continuous infusion

A glucagon analog designed to allow for continuous subcutaneous infusion via a wearable pump system for the treatment of Congenital Hyperinsulinism (CHI).

Short Bowel Syndrome

Glepaglutide

A long-acting GLP-2 analog designed to reduce or eliminate the need for parenteral support in SBS patients with intestinal failure.

Obesity

Dapiglutide (program paused)

A long-acting GLP-1/GLP-2 receptor dual agonist (Phase 2 ready)

Obesity

As one of the greatest healthcare challenges of our time, obesity and overweight are associated with more than 220 complications and comorbidities, including cardiovascular disease, liver disease, type 2 diabetes, kidney disease, and neuroinflammation. Zealand Pharma is focused on reprogramming metabolic health to increase healthspan, not just treat symptoms.

Rare diseases

Severely impacting quality of life, many rare diseases represent major unmet needs. Zealand Pharma has a long-standing commitment to people living with congenital hyperinsulinism (CHI) and short bowel syndrome (SBS).

Congenital hyperinsulinism Short Bowel Syndrome

Chronic inflammation

Through damage to tissues and organs, chronic inflammation can lead to the development of a broad range of potentially disabling or life-threatening illnesses. Zealand Pharma believes peptide medicines present opportunities for innovation in the treatment of chronic inflammatory diseases.

Safety, tolerability, and clinical effects of petrelintide (ZP8396), a long-acting amylin analog

Featured publication

Results from a 16-week Phase 1 multiple ascending dose (MAD) trial of petrelintide (ZP8396) presented at Obesity Week in November 2024.

Fostering an enriching workplace

At Zealand, we promote engagement, growth, diversity and inclusion. We believe that engaged and motivated employees with a passion for making a difference bring a positive mindset and inspiring level of energy to work. Our highly skilled employees are at the center of the medical treatment options that we design and develop for patients. We pride ourselves on our ability to work together as one team and to foster a strong and engaging company culture founded on collaboration, courage, empowerment, and trust.